Clinical Trials Logo

Preleukemia clinical trials

View clinical trials related to Preleukemia.

Filter by:

NCT ID: NCT06113302 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Start date: March 1, 2024
Phase: Early Phase 1
Study type: Interventional

To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.

NCT ID: NCT06109064 Recruiting - Clinical trials for Myelodysplastic Syndromes

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Start date: October 27, 2023
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned MDS patients by observing the factors related to the efficacy and adverse reactions.

NCT ID: NCT06091267 Recruiting - Clinical trials for Myelodysplastic Syndromes

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Start date: October 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an Open-Label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 versus IV Decitabine in Chinese Subjects with Myelodysplastic Syndromes

NCT ID: NCT06073860 Recruiting - Clinical trials for Myelodysplastic Syndrome

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

Start date: November 2, 2023
Phase:
Study type: Observational

The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.

NCT ID: NCT06063486 Recruiting - Clinical trials for Myelodysplastic Syndrome

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.

NCT ID: NCT06046313 Recruiting - Clinical trials for Acute Myeloid Leukemia

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Start date: October 19, 2023
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.

NCT ID: NCT06045689 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

MAXILUS
Start date: October 5, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.

NCT ID: NCT06001385 Recruiting - Lymphoma Clinical Trials

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

OPTIMIZE
Start date: December 8, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

NCT ID: NCT05970822 Recruiting - Clinical trials for Myelodysplastic Syndromes

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Start date: June 18, 2023
Phase: Phase 1
Study type: Interventional

The study is to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of BC3402 in combination with azacitidine (AZA) in subjects with Myelodysplastic Syndrome (MDS) and Chronic myelomonocytic leukemia (CMML)

NCT ID: NCT05961839 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: September 27, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.